Tag: HER2-expressing cancers
First Patient Dosed in Phase 1 Study of Next Generation Antibody-Drug...
BYON3521, a new ADC targeting c-Met, has entered phase 1 (BYON3521.001/NCT05323045) clinical development when, earlier this week, a first patients had been dosed with the investigational drug being developed...
Byondis and Medac Sign Collaboration and Supply Agreements for Trastuzumab Duocarmazine
Dutch clinical stage biopharmaceutical company Byondis has entered into a license, collaboration and supply agreement with Medac, a privately owned pharmaceutical company based in Germany.
Byondis...
Remegen’s Disitamab Vedotin Attracts China’s largest-ever out-license Agreement at US $...
Earlier this month, Remegen Biosciences, a Shandong-based biotech company operating since 2008, scored the largest ever out-license deal for a Chinese biotech company when...
U.S. Patent for Bolt Biotherapeutics’ Boltbody™ ISAC Platform Technology is a...
San Francisco Bay Area-based Bolt Biotherapeutics confirmed that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,675,358 entitled "Antibody Adjuvant...
RC48-ADC Demonstrates Clinically Meaningful Results in HER2+ Metastatic and Unresectable Urothelial...
Clinically meaningful topline results for a Phase II clinical trial of RC48-ADC were presented during the annual meeting of the American Society of Clinical...
